Physician profile
Sayed Elsayyad
NPI 1093764953
$5,030.83
in general payments reported to CMS, 2019-2025
45 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $962 · 2020: $446 · 2021: $1,183 · 2022: $956 · 2023: $547 · 2024: $588 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,484.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $384.06 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $330.08 | 2022-2025 | Tezspire |
| Novo Nordisk INC | $319.69 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $313.68 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $313.59 | 2019-2024 | |
| Amgen INC. | $306.04 | 2019-2024 | Prolia, Evenity |
| Esperion Therapeutics, INC. | $290.28 | 2021-2022 | |
| Lilly USA, LLC | $277.30 | 2019-2024 | Mounjaro |
| Gilead Sciences, INC. | $254.51 | 2019-2025 | Yeztugo |
| Acadia Pharmaceuticals INC | $246.14 | 2019-2023 | Nuplazid |
| Abbvie INC. | $206.52 | 2021-2023 | |
| Abbott Laboratories | $202.84 | 2023-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $199.30 | 2021-2025 | Rexulti |
| Horizon Therapeutics Plc | $189.56 | 2019-2023 | Krystexxa |
| Ascensia Diabetes Care US INC. | $123.24 | 2023 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sayed Elsayyad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.